ASCO GU Symposium 2022
ASCO GU Symposium 2022
American Society of Clinical Oncology Genitourinary Cancers Symposium 2022
GU Oncology Now EditorsASCO GU Symposium 2022 | February 21, 2022
Study findings associate pre- and posttreatment PSMA expression with prostate-specific antigen response and overall survival.
Read More
GU Oncology Now EditorsASCO GU Symposium 2022 | February 21, 2022
Trial oncolytic measles virus encoding thyroidal sodium iodide symporter treatment may be effective in patients with UC.
GU Oncology Now EditorsASCO GU Symposium 2022 | February 21, 2022
Avelumab plus docetaxel was safe and demonstrated promising efficacy for patients with metastatic urothelial carcinoma.
GU Oncology Now EditorsASCO GU Symposium 2022 | February 21, 2022
Study results demonstrate a conclusive pattern of distinct molecular alterations among metastatic sites in patients with RCC.
GU Oncology Now EditorsASCO GU Symposium 2022 | February 20, 2022
A study compared genomic profiles of locally advanced or metastatic UCs with squamous differentiation to standard UC.
GU Oncology Now EditorsASCO GU Symposium 2022 | February 20, 2022
A follow-up to the VISION trial compared associations of exposure and treatment-emergent adverse events frequency.
GU Oncology Now EditorsASCO GU Symposium 2022 | February 20, 2022
Pembrolizumab and lenvatinib didn’t effectively improve clinical outcomes for patients with locally advanced or metastatic ...
GU Oncology Now EditorsASCO GU Symposium 2022 | February 20, 2022
Collaborators evaluated trimodality therapy and radical cystectomy and found TMT was effective for select patients with MIBC.
GU Oncology Now EditorsASCO GU Symposium 2022 | February 18, 2022
Pembrolizumab plus abiraterone acetate and prednisone may be beneficial for treating chemotherapy-naïve patients with mCRPC.
GU Oncology Now EditorsASCO GU Symposium 2022 | February 18, 2022
Researchers quantified the absorbed dose of 177Lu-PSMA-617 in organs at risk for radiotoxicity among patients with mCRPC.
GU Oncology Now EditorsASCO GU Symposium 2022 | February 18, 2022
Investigators assessed pembrolizumab, with or without chemotherapy, versus chemotherapy alone in patients with advanced UC.
GU Oncology Now EditorsASCO GU Symposium 2022 | February 18, 2022
Researchers assessed 177Lu-PSMA treatment outcomes in patients who would have failed the VISION trial’s inclusion criteria.
Advertisement
Advertisement